Drugs / TNF Kinoid
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01911234 | Sep 2013 → Sep 2014 | rheumatoid arthritis | Neovacs | Completed | No outcome recorded |
| Phase 2 | NCT01291810 | Feb 2011 → Oct 2012 | Crohn disease | Neovacs | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TNF Kinoid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01291810 ↗ |
| Known as | TNF-K | “The safety and immunogenicity of the TNF-Kinoid (TNF-K) have been evaluated in a phase II clinical study conducted in subjects with Rheumatoid arthritis.” NCT01911234 ↗ |
| Route | Intramuscular | “IM administration” NCT01911234 ↗ |